These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21167859)

  • 1. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials.
    Tielemans CL; Vlasak J; Kosa D; Billiouw JM; Verpooten GA; Mezei I; Ryba M; Peeters PC; Mat O; Jadoul MY; Polakovic V; Dhaene M; Treille S; Kuriyakose SO; Leyssen M; Houard SA; Surquin M
    Vaccine; 2011 Feb; 29(6):1159-66. PubMed ID: 21167859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency.
    Surquin M; Tielemans C; Nortier J; Jadoul M; Peeters P; Ryba M; Roznovsky L; Domán J; Barthelemy X; Crasta PD; Messier M; Houard S
    Hum Vaccin; 2011 Sep; 7(9):913-8. PubMed ID: 21892006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine.
    Surquin M; Tielemans CL; Kulcsár I; Ryba M; Vörös P; Mat O; Treille S; Dhaene M; Stolear JC; Kuriyakose SO; Leyssen MX; Houard SA
    Kidney Int; 2010 Feb; 77(3):247-55. PubMed ID: 19940840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients.
    Nevens F; Zuckerman JN; Burroughs AK; Jung MC; Bayas JM; Kallinowski B; Rivas EF; Duvoux C; Neuhaus P; Saliba F; Buti M; Zarski JP; Pons F; Vanlemmens C; Hamtiaux V; Stoffel M
    Liver Transpl; 2006 Oct; 12(10):1489-95. PubMed ID: 16964595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.
    Hernández-Bernal F; Aguilar-Betancourt A; Aljovin V; Arias G; Valenzuela C; de Alejo KP; Hernández K; Oquendo O; Figueredo N; Figueroa N; Musacchio A; Véliz G; García E; Mollineda AD; Juvier AI; Trujillo J; Delahanty A; Ortega D; Cinza Z; González VL
    Hum Vaccin; 2011 Oct; 7(10):1026-36. PubMed ID: 21941089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous vaccination against hepatitis A and B: results of an open, randomized study from the occupational health point of view.
    Rieger MA; Hofmann F; Michaelis M
    Int J Occup Med Environ Health; 2004; 17(3):379-91. PubMed ID: 15683159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth.
    Jafarzadeh A; Montazerifar SJ
    J Ayub Med Coll Abbottabad; 2006; 18(4):4-9. PubMed ID: 17591001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates.
    Jafarzadeh A; Zarei S; Shokri F
    Vaccine; 2008 Jan; 26(2):269-76. PubMed ID: 18037544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C.
    Kallinowski B; Jilg W; Buchholz L; Stremmel W; Engler S
    Z Gastroenterol; 2003 Oct; 41(10):983-90. PubMed ID: 14562195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients.
    Tong NK; Beran J; Kee SA; Miguel JL; Sánchez C; Bayas JM; Vilella A; de Juanes JR; Arrazola P; Calbo-Torrecillas F; de Novales EL; Hamtiaux V; Lievens M; Stoffel M
    Kidney Int; 2005 Nov; 68(5):2298-303. PubMed ID: 16221232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of hepatitis B vaccine among hemodialysis patients: effect of revaccination of non-responders and duration of protection.
    Chaves SS; Daniels D; Cooper BW; Malo-Schlegel S; Macarthur S; Robbins KC; Kobetitsch JF; McDaniel A; D'Avella JF; Alter MJ
    Vaccine; 2011 Dec; 29(52):9618-23. PubMed ID: 22044739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy infants.
    Vesikari T; Martin JC; Liss CL; Liska V; Schödel FP; Bhuyan PK
    Pediatr Infect Dis J; 2011 Jul; 30(7):e109-13. PubMed ID: 21552183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease.
    Weinstein T; Chagnac A; Boaz M; Ori Y; Herman M; Zevin D; Schmilovitz-Weiss H; Gafter U
    Nephron Clin Pract; 2004; 97(2):c67-72. PubMed ID: 15218332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenge with hepatitis B vaccine in children previously vaccinated with a hepatitis B-containing combination vaccine.
    Reinert P; Cinquetti S; Soubeyrand B; Biasio LR; Meghlaoui G; Thomas S; Watson M
    Adv Ther; 2010 Jan; 27(1):28-38. PubMed ID: 20182924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
    Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
    Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination.
    Evans TG; Schiff M; Graves B; Agosti J; Barritt ML; Garner D; Holley JL
    Clin Nephrol; 2000 Aug; 54(2):138-42. PubMed ID: 10968690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
    Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
    J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
    Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
    Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunogenicity of vaccines against viral hepatitis A and B in the population above 40 years of age -- impact of risk factors].
    Chlíbek R; Smetana J; Sindelár R; Cecetková B; Prymula R; Kohl I
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):119-28. PubMed ID: 17900060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand.
    Poovorawan Y; Chongsrisawat V; Theamboonlers A; Bock HL; Leyssen M; Jacquet JM
    Vaccine; 2010 Jan; 28(3):730-6. PubMed ID: 19892043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.